Latest Pre-clinical development Stories
-- hGH-CTP and MOD-6030 to be Featured in Oral and Poster Presentations at Endocrine Society's Annual Meeting -- SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of...
FARMINGTON, Conn., May 15, 2013 /PRNewswire-iReach/ -- World Pharma Congress is celebrating 12 years of preclinical research with its annual event covering the latest in drug targets, high-throughput screening, lead optimization, ADME and drug safety. Years of effectively covering the latest preclinical strategies and technologies that drive better predictions has culminated in priming this year's event to move further downstream into early formulations and drug delivery. (Photo:...
AMSTERDAM, May 6, 2013 /PRNewswire/ -- PharmaPendium Metabolizing Enzymes and Transporters Module delivers comprehensive visibility of Drug-Drug-Interactions Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical and medical information products and services, today announces that PharmaPendium [http://www.elsevier.com/pharmapendium ], the leading source of preclinical, clinical and post-market data, has...
Integral BioSystems will exhibit and offer its drug development expertise to attendees at the ARVO Annual Meeting at the Washington State Convention Center in Seattle, WA from May 5, 2013 through May 9, 2013 in Exhibitor Booth #517. Bedford, MA (PRWEB) May 05, 2013 The 2013 Meeting of the Association for Research and Vision in Ophthalmology, being held at the Washington State Convention Center in Seattle, WA combines a wide range of talks from commercial and academic figures in...
Altogen Labs is a GLP compliant laboratory that provides preclinical research and biology contract research services (CRO). Altogen Labs now offers wide variety of preclinical CRO services, including drug development, generation of stable cell lines, RNAi gene silencing and in vivo research services (xenograft, in vivo siRNA delivery), pharm/tox assays (IC50), cell banking, and ELISA assay development. Austin, TX (PRWEB) April 26, 2013 Altogen Labs, a biotechnology company focused on...
NES-ZIONA, Israel, March 5, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent application covering the company's long-acting CTP-enhanced human growth hormone (hGH-CTP). Upon issuance, the new patent will provide PROLOR with additional intellectual property protection that covers methods for decreasing body fat in humans through the use of hGH-CTP...
Edgemont Capital serves as exclusive advisor to Miami Research Associates in transaction NEW YORK and MIAMI, Feb. 26, 2013 /PRNewswire/ -- Edgemont Capital Partners, L.P., a boutique investment bank focused on the merger and acquisition advisory needs of healthcare companies, announces the sale of Miami Research Associates ("MRA"), to QPS, LLC. MRA, a multi-therapeutic provider of clinical research services for drug development focused on conducting clinical studies in patient...
PRINCETON, N.J., Dec. 3, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that its early development facility located in Shanghai, China, has received a Good Laboratory Practice (GLP) Certificate from the State Food and Drug Administration (SFDA) of the People's Republic of China. The Covance facility in Shanghai provides nonclinical safety assessment, bioanalytical, in vivo pharmacology, and DMPK services. Since opening its early development facility in Shanghai in...
NES-ZIONA, Israel, Nov. 13, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a patent application covering the company's long-acting reversible-pegylation technology (RPeg). Upon issuance, the new patent will provide added intellectual property protection, including additional compositions and configurations of long-acting drug product, in addition to the already-issued U.S. patent...
NES-ZIONA, Israel, Oct. 16, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced positive results from a preclinical toxicology study designed to assess the safety and tolerability of PROLOR's proprietary long-acting reversible-pegylation technology ("RPeg"). The study results demonstrate that RPeg was safe and well-tolerated at high doses following repeated administration in rats. The RPeg platform has been utilized to develop PROLOR's preclinical drug...
